Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the way of significant clinical advance. But now, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) are breaking through that barrier. They show, for the first time in an animal model, that tau pathology – the second-most important lesion in the brain in patients with Alzheimer’s disease – can be reversed by a drug.
“We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,” explained senior investigator Domenico Praticò, MD, Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple at LKSOM. The study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.
The researchers landed on their breakthrough after discovering that inflammatory molecules known as leukotrienes are deregulated in Alzheimer’s disease and related dementias. In experiments in animals, they found that the leukotriene pathway plays an especially important role in the later stages of disease.
“At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,” Dr. Praticò said. “Having discovered this, we wanted to know whether blocking leukotrienes could reverse the damage, whether we could do something to fix memory and learning impairments in mice having already abundant tau pathology.”
To recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Praticò and colleagues used specially engineered tau transgenic mice, which develop tau pathology – characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability – as they age. When the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits leukotriene formation by blocking the 5-lipoxygenase enzyme.
After 16 weeks of treatment, animals were administered maze tests to assess their working memory and their spatial learning memory. Compared with untreated animals, tau mice that had received zileuton performed significantly better on the tests. Their superior performance suggested a successful reversal of memory deficiency.
To determine why this happened, the researchers first analyzed leukotriene levels. They found that treated tau mice experienced a 90-percent reduction in leukotrienes compared with untreated mice. In addition, levels of phosphorylated and insoluble tau, the form of the protein that is known to directly damage synapses, were 50 percent lower in treated animals. Microscopic examination revealed vast differences in synaptic integrity between the groups of mice. Whereas untreated animals had severe synaptic deterioration, the synapses of treated tau animals were indistinguishable from those of ordinary mice without the disease.
“Inflammation was completely gone from tau mice treated with the drug,” Dr. Praticò said. “The therapy shut down inflammatory processes in the brain, allowing the tau damage to be reversed.”
The study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma. “Leukotrienes are in the lungs and the brain, but we now know that in addition to their functional role in asthma, they also have a functional role in dementia,” Dr. Praticò explained.
“This is an old drug for a new disease,” he added. “The research could soon be translated to the clinic, to human patients with Alzheimer’s disease.”
The Latest on: Dementia
via Google News
The Latest on: Dementia
Early Dementia Detected in Hypertensive Patients Using MRI
on June 13, 2018 at 7:21 am
Data over the past several years have pointed toward the hypothesis that hypertension is a prevailing risk factor for the development of dementia. While conventional neuroimaging techniques have provided some insight into the development of ... […]
High Blood Pressure in Your 50s May Set Stage for Dementia
on June 13, 2018 at 6:48 am
WEDNESDAY, June 13, 2018 (HealthDay News) -- Elevated blood pressure in your 50s might raise your risk of developing dementia later in life, a new European study has found. People with a systolic blood pressure of 130 or more at age 50 were 45 percent more ... […]
Dementia can be caused by hypertension
on June 13, 2018 at 6:15 am
A new study in Cardiovascular Research, published by Oxford University Press, indicates that patients with high blood pressure are at a higher risk of developing dementia. This research also shows (for the first time) that an MRI can be used to detect very ... […]
Slight raise in blood pressure by 50 could increase dementia risk by 45 per cent
on June 13, 2018 at 4:00 am
Currently, around seven million Britons whose blood pressure exceeds 140/90 mmHg are recommended by GPs to take medication to control it. But NHS watchdogs are considering bringing the threshold down further, in line with US advice which recommends drugs ... […]
Even slightly elevated blood pressure increases dementia risk
on June 13, 2018 at 3:18 am
The link between the risk of dementia and hypertension is well established. What about higher-than-normal blood pressure in the absence of a hypertension diagnosis, however? But what is "middle age," exactly? And does blood pressure need to become so high ... […]
Raised blood pressure heightens risk of dementia, major UCL study finds
on June 12, 2018 at 5:05 pm
Slightly raised blood pressure in middle age could increase the risk of dementia by up to 45 per cent, new research shows. A study of almost 9,000 civil servants found that 50-year-olds with readings of more than 130/80 had a far greater chance of ... […]
Dementia risk to 50-year-olds with raised blood pressure – study
on June 12, 2018 at 4:32 pm
Association between blood pressure and dementia risk was seen at aged 50, but not 60 or 70, the study found. Photograph: Anthony Devlin/PA Fifty-year-olds with slightly raised blood pressure are at an increased risk of getting dementia in later life, a new ... […]
Dementia risk increased in 50-year-olds with blood pressure below hypertension threshold
on June 12, 2018 at 4:06 pm
New findings from the long-running Whitehall II study of over 10,000 civil servants has found 50-year-olds who had blood pressure that was higher than normal but still below the threshold commonly used when deciding to treat the condition, were at ... […]
High Blood Pressure at Age 50 Tied to Dementia Risk
on June 12, 2018 at 4:05 pm
Elevated blood pressure at age 50 is linked to an increased risk for dementia in later years, a new study reports. The research, published in the European Heart Journal, found that systolic blood pressure (the top number) as low as 130 increased the risk ... […]
via Bing News